|
Report Date : |
22.04.2014 |
IDENTIFICATION DETAILS
|
Name : |
P.T. PACIFIC BIOTEKINDO INTRALAB |
|
|
|
|
Registered Office : |
Komplek Perkantoran Taman Pulo Gebang Blok A3 No.17-20, Jl. Raya Bekasi Km. 24, Jakarta 13910 |
|
|
|
|
Country : |
Indonesia |
|
|
|
|
Date of Incorporation : |
15.02.1996 |
|
|
|
|
Com. Reg. No.: |
No. AHU-AH.01.10-52406 |
|
|
|
|
Legal Form : |
Limited Liability Company |
|
|
|
|
Line of Business : |
Trading, Import and Distribution of Laboratory Equipments and
Diagnostic Products |
|
|
|
|
No. of Employees : |
20 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made on
e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31, 2014
|
Country Name |
Previous Rating (31.12.2013) |
Current Rating (31.03.2014) |
|
Indonesia |
B1 |
B1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
INDONESIA - ECONOMIC OVERVIEW
Indonesia, a vast polyglot
nation, has grown strongly since 2010. During the global financial crisis,
Indonesia outperformed its regional neighbors and joined China and India as the
only G20 members posting growth. The government has promoted fiscally
conservative policies, resulting in a debt-to-GDP ratio of less than 25% and
historically low rates of inflation. Fitch and Moody's upgraded Indonesia's
credit rating to investment grade in December 2011. Indonesia still struggles
with poverty and unemployment, inadequate infrastructure, corruption, a complex
regulatory environment, and unequal resource distribution among regions. The
government also faces the challenges of quelling labor unrest and reducing fuel
subsidies in the face of high oil prices.
|
Source
: CIA |
Name of Company :
P.T. PACIFIC
BIOTEKINDO INTRALAB
A d d r e s s :
Head Office
Komplek Perkantoran Taman Pulo Gebang Blok A3 No.17-20
Jl. Raya Bekasi Km. 24
Jakarta 13910
Indonesia
Phones -
(62-21) 461 4066 (hunting)
Fax. - (62-21) 461 4692
Email - sales@pacbiotekindo.co.id
and corp@pacbiotekindo.co.id
Building Area - 2 storey
Office Space - 240 sq. meters
Region - Commercial
Status - Owned
Date of
Incorporation :
15 February 1996
Legal Form :
P.T. (Perseroan Terbatas) or Limited Liability Company
Company Reg. No. :
The Ministry of Law and Human Rights
a. No. C2-4899.HT.01.01.Th.96
Dated 6 March 1996
b. No. AHU-27913.AH.01.02.Tahun 2009
Dated 23 June 2009
c. No. AHU-AH.01.10-52406
Dated 04 December 2013
Company Status :
National Private Company
Permit by the
Government Department :
The Department of Finance
NPWP No. 01.674.643.0-007.000
Related/Affiliated Company :
Not available
Capital Structure
:
Authorized Capital -
Rp. 12,000,000,000.-
Issued Capital -
Rp. 3,000,000,000.-
Paid up Capital -
Rp. 3,000,000,000.-
Shareholders/Owners
:
a. Mr. Suroso - Rp.
2,970,000,000.- (99%)
Address:
Komp. Taman Modern Blok A.4/2
RT.002/006,
Cakung
East Jakarta
b. Mr. Bintaryo -
Rp. 30,000,000.- ( 1%)
Address:
Jl. Bojong Molek XIII C.56/1
RT.010/014,
Rawa Lumbu, Bekasi
West Java
Lines of Business
:
Trading, Import and Distribution of Laboratory Equipments and Diagnostic
Products
Sole Agent and
Distributor of :
a. Inverness Medical Innovation of Australia
b. IDL Biotech AB of Sweden
c. INOVA diagnostics of the USA
d. Zeus Scientific Inc., of the USA
e. Awarenes technology Inc., of the USA
f.
Indec Diagnostics of Indonesia
g. DiaSorin Spa., of Italy
h. Scholly Fiberoptics GmbH of Germany
Total Investment :
None
Started Operation
:
1996
Brand Name :
None
Technical
Assistance :
None
Number of Employee
:
20 persons
Marketing Area :
Domestic - 100%
Main Customers :
a. Agent and Distributor of Laboratory and Medical Equipments
b. Universities and Institutes
c. Etc.
Market Situation :
Very Competitive
Main Competitors :
a. PT. Abadi Sekawan Murni
b. PT. Besindo Medi Farma
c. PT. Cahaya Esa Karunia Optima
d. PT. Demka Sakti
e. PT. Era Karsa Mandiri
f. PT. Harindo Jaya International
g. PT. Megah Medika Farma
h. PT. Nusantara Bina Diagnostika
i. PT. Indofa Utama Multi Core
Business Trend :
Growing
B a n k e r s :
a. P.T. Bank MANDIRI Tbk.
Bekasi Branch
West Java
Indonesia
b. P.T. Bank CENTRAL ASIA Tbk.
Bekasi Branch
West Java
Indonesia
Auditor :
Internal Auditor
Litigation :
No litigation record in our database
Annual Sales
(Estimated) :
2011 – Rp. 42.5 billion
2012 – Rp. 48.0 billion
2013 – Rp. 55.0 billion
Net Profit
(estimated) :
2011 – Rp. 1.9 billion
2012 – Rp. 2.2 billion
2013 – Rp. 2.5 billion
Payment Manner :
Almost Promptly
Financial Comments
:
Satisfactory
Board of Management :
Director - Mr. Sugianto Hondopranoto
Board of Commissioner :
Commissioner - Mr. Suroso
Signatories :
Director (Mr. Sugianto Hondopranoto)
which must be approved by Board of Commissioner (Mr. Suroso)
Management Capability :
G o o d
Business Morality :
G o o d
P.T. PACIFIC BIOTEKINDO INTRALAB (P.T. PBI) was established in Jakarta
on February 1996 with an authorized capital of Rp 200,000,000.- of which Rp
100,000,000.- was issued and fully paid up.
The founding shareholders of the company are Mr. Suroso (98%) and Mr.
Adie Suryo (2%), both are indigenous businessmen. The Deed of establishment has
been approved by the Minister of Justice of the Republic of Indonesia through Decree No. C2-4899.HT.01.01.Th.96
dated March 6, 1996.
The
articles of association of the company have frequently been changed, most
recently by notarial deed number 14 dated November 25, 2013 was made by notary Anisah
Abubakar, SH., the authorized capital was raised to Rp 12,000,000,000.- of
which Rp 3,000,000,000.- was issued and fully paid up. The latest shareholders are Mr. Suroso (99%)
and Mr. Bintaryo (1%). The amendment to deed
has been approved by the Minister of Law and Human Rights of the Republic of
Indonesia through its Decree No. AHU-AH.01.10-52406 dated December 4, 2013.
P.T. PBI has been operating commercially since early of 1996 in trading, import and distributor of laboratory equipments, diagnostic and immunology products. Mr. Suroso, the owned of the company
explained that P.T. PBI is an agent and distributor for several trade-marks of
the above products such as; Inverness Medical Innovation of Australia, IDL
Biotech AB of Sweden, INOVA Diagnostic of the USA, Zeus Scientific Inc., of the
USA, Indec Diagnostics of Indonesia, DiaSorin Spa of Italy and Scholly
Fiberoptics GmbH of Germany. The
products are sold to government and the private sector, including distributors
and agents of Laboratory and medical equipment in the country like C.V.
EKARITAMA LESTARI in Jakarta, CV. PESONA SCIENTIFIC in Bandung, PT. PROTEUSSABA
NUSANTARA in Medan, PT. BIOTRONINDO PERSADA in Padang, CV. MEDILAB UTAMA in
Bengkulu, PT. UTAMA BINAFARMA in Pontianak and others. In addition, P.T. PBI is also negotiating a
business cooperation with Bandung Institute of Technology (ITB) in Bandung,
Gajah Mada University in Yogyakarta and others.
We observe that P.T. PBI is classified as a medium sized company of its
kind in the country of which the operation has been growing in the last three
years.
The domestic demand for laboratory & scientific instrument,
laboratory chemical and glassware products had been rising by 8% to 10% on the
average per annum in the last five years in line with the rapid growth of
various industrial sectors including hospitals, pharmaceutical industries,
cosmetic industries, universities and others in the above period of times as
the consumers. But, later dwindled as the global economic slowdown since October
2008, followed by tight money policy imposed by Indonesian Central Bank (Bank
Indonesia) and also heated by political issue in the country. The demand growth
started to awake in June 2009 in line with the amelioration of economic
condition in the country. Market
competition is very tough on account of large number of other similar companies
operating in the country. P.T. PBI business position in this case is not too
badly because it has built regular customers and extensive marketing network
all across the country.
Until this time P.T. PBI has not
been registered with Indonesian Stock Exchange, so that they shall not obliged
to announce their financial statement.
Therefore, the company has no obligation to publish financial statement
publicly. We have checked to Department of Trade and Industry and found that no
financial statement has been reported. P.T. PBI’s management is very reclusive
to outsider and rejecting to disclose its financial condition but we estimated
the total sales turnover of P.T. PBI in 2011 amounted to Rp. 42.5 billion
increased to Rp. 48.0 billion in 2012 and rose again to Rp. 55.0 billion in
2013. The company operation has gained a net profit of Rp. 2.5 billion in 2013
and the company has a total assets at least Rp. 15.0 billion. It’s projected
the sales turnover it will be higher by at least 8% in 2014. So far, we did not hear that the company
having been black listed by the Central Bank (Bank Indonesia). The company
usually pays its debts punctually to suppliers.
The management is headed by Mr. Sugianto Hondopranoto (57) as
Director. But, the prime-mover of the
company is Mr. Suroso (54), a businessman with more than 18 years experience in
trading and distribution of laboratory equipment, diagnostic and immunology
products. The management is having maintained a wide business relation with
private businessmen at home and abroad as well as with government sectors. So
far we did not hear that the company’s management having been involved in
business malpractices or detrimental cases that settled in the country. The
company’s litigation record is clean and it has not registered with the black
list of Bank of Indonesia. We have investigated to the district court and the
high court in Indonesia, but there is no file contained civil or criminal cases
involved the company management.
We appraise that P.T. PACIFIC BIOTEKINDO INTRALAB is quite feasible for
business transaction. But owing to the global economic turmoil we recommend to
treat prudently in extending loan to the company.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.34 |
|
|
1 |
Rs.101.41 |
|
Euro |
1 |
Rs.83.38 |
INFORMATION DETAILS
|
Analysis Done by
: |
DIV |
|
|
|
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.